Macrocyclic kinase inhibitors

Details Macrocyclic kinase inhibitors Macrocyclic kinase inhibitors

2007-03-27

2009-10-13

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C549S267000

Reexamination Certificate

active

07601852

ABSTRACT:
A compound having a structure according to formula Iwherein R1, R2, R3, R4, and R5are as defined herein, are useful as kinase inhibitors.

REFERENCES:
patent: 5795910 (1998-08-01), Giese
patent: 6635671 (2003-10-01), Kastelic et al.
patent: 2004/0224936 (2004-11-01), Chiba
patent: 2005/0182129 (2005-08-01), Ikeda
patent: 2005/0256183 (2005-11-01), Kasibhatla
patent: 2006/0079494 (2006-04-01), Santi
patent: 2006/0094674 (2006-05-01), Neel
patent: 0606044 (1994-07-01), None
patent: 2323845 (1998-10-01), None
patent: 2323845 (1998-10-01), None
patent: 08-040893 (1996-02-01), None
patent: 2001-294527 (2001-10-01), None
patent: WO 02/48135 (2002-06-01), None
patent: WO 02/48136 (2002-06-01), None
Patani et al. Chem.Rev. 1996, 96, 3147-3176.
Horn et al. J. Med. Chem. 1984,27, 1340-1343.
Davies et al.,Nature2002, 417, 949-954, “Mutations of the BRAF Gene in Human Cancer”.
Dombrowski et al.,J. Antibiotics1999, 52 (12), 1077-1085, “Production of a Family of Kinase-Inhibiting Lactones from Fungal Fermentations”.
Ellestad et al.,J. Org. Chem. 1980, 43 (12), 2339-2343, “New Zearalenone Related Macrolides and Isocoumarins from an Unidentified Fungus”.
Nair et al.,Tetrahedron Letters1980, 21 (21), 2011-2012, “Metabolites of pyrenomycetes. XIII. Structure of (+)-hypothemycin, an antibiotic macrolide fromHypomyces trichothecoides” (abstract).
Sausville et al.,Ann. Rev. Pharmacol. Toxicol. 2003, 43, 199-231, “Signal Transduction-Directed Cancer Treatments”.
Selles et al.,Tetrahedron Letters2002, 43 (26), 4627-4631, “Convergent stereospecific synthesis of LL-Z1640-2 (or C292), hypothemycin and related macrolides. Part 2”.
Tatsuta et al.,Chemistry Letters2001, 2, 172-173, “The First Total Synthesis of a Macrocyclic Antiprotozoan, LI-Z1640-2”.
Wermuth, ed.,The Practice of Medicinal Chemistry, 2nd Ed., pp. 561-586 (Academic Press 2003).
Williams et al.,Biochemistry1998, 37, 9579-9585, “Ro 09-2210 Exhibits Potent Antiproliferative Effects on Activated T Cells by Selectively Blocking MKK Activity”.
Patani et al., Bioisosterism: A Rational Approach in Drug Design, Chem. Rev., vol. 96, pp. 3147-3176 (1996).

Affiliated with

Also associated with

Rating

Macrocyclic kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Macrocyclic kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrocyclic kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4095676